VEGFA and Kaposi's sarcoma: Some KS lesions respond to single agent VEGF inhibitors such as bevacizumab, a recombinant monoclonal antibody (mAb) directed against VEGF-A [18–20]; other lesions require aggressive cytotoxic chemotherapy.